This study aims to summarize the clinical characteristics of death cases with COVID-19 and to identify critically ill patients of COVID-19 early and reduce their mortality. Methods: The clinical records, laboratory findings and radiological assessments included chest X-ray or computed tomography were extracted from electronic medical records of 25 died patients with COVID-19 in Renmin Hospital of Wuhan University from Jan 14 to Feb 13, 2020. Two experienced clinicians reviewed and abstracted the data. Results: The age and underlying diseases (hypertension, diabetes, etc.) were the most important risk factors for death of COVID-19 pneumonia. Bacterial infections may play an important role in promoting the death of patients. Malnutrition was common to severe patients. Multiple organ dysfunction can be observed, the most common organ damage was lung, followed by heart, kidney and liver. The rising of neutrophils, SAA, PCT, CRP, cTnI, D-dimer, LDH and lactate levels can be used as indicators of disease progression, as well as the decline of lymphocytes counts. Conclusions: The clinical characteristics of 25 death cases with COVID-19 we summarized, which would be helpful to identify critically ill patients of COVID-19 early and reduce their mortality.

This retrospective study aimed to analysis clinical characteristics and outcomes of cancer patients with novel coronavirus disease‐19 (COVID‐19). Medical records, laboratory results and radiologic findings of 52 cancer patients with COVID‐19 were collected, clinical characteristics and outcomes were summarized. A total of 52 cancer patients with COVID‐19 were included. Median age of 52 cancer patients with COVID‐19 was 63 years (34‐98). Thirty‐three (63.5%) patients were mild and 19 (36.5%) were severe/critical. Lung cancer was the most frequent cancer type (10, 19.2%). The common symptoms were as follows: fever (25%), dry cough (17.3%), chest distress (11.5%), and fatigue (9.6%). There were 33 (63.5%) patients had comorbidities, the most common symptom was hypertension (17, 51.5%). Twenty‐six (78.8%) patients developed pneumonia on admission. Lymphocytes (0.6 × 109/L) decreased in both mild and severe/critical patients. Median levels of D‐dimer, C‐reactive protein, procalcitonin, and lactate dehydrogenase were 2.8 mg/L, 70.5 mg/L, 0.3 ng/mL, and 318 U/L, respectively, which increased significantly in severe/critical patients compared with the mild patients. Interleukin‐6 (12.6  pg/mL) increased in both mild and severe/critical patients, there was a significant difference between them. Complications were observed in 29 (55.8%) patients, such as liver injury (19, 36.5%), acute respiratory distress syndrome (9, 17.3%), sepsis (8, 15.4%), myocardial injury (8, 15.4%), renal insufficiency (4, 7.7%), and multiple organ dysfunction syndrome (3, 5.8%). Eleven (21.2%) patients with cancer died. The infection rate of severe acute respiratory syndrome coronavirus 2 in patients with cancer was higher than the general population, cancer patients with COVID‐19 showed deteriorating conditions and poor outcomes.

Objective: This retrospective study aimed to analysis the clinical characteristics and complications in death cases with novel coronavirus disease-19 . Method: We collected the medical records of 92 patients with COVID-19 in Renmin Hospital of Wuhan University who died during January 6th to February 25th, 2020, summarized the clinical characteristics of complications. Results: There were 91 death cases who developed different complications including acute respiratory distress syndrome (ARDS) (73/91), myocardial injury (31/91), liver injury (15/91), renal insufficiency (14/91), multiple organ dysfunction syndrome (MODS) (14/91) and pneumothorax (1/91). Among these patients, 83 patients had at least one complication. While 1 patient who died of recurrent gastrointestinal bleeding was not directly linked to COVID-19. Conclusion: The main complications of deceased patients with COVID-19 were ARDS, myocardial injury, liver injury, renal insufficiency and MODS.

We report a novel biochemical method based on the sacrificial hydrogen strategy to synthesize bimetallic gold (Au)–palladium (Pd) nanoparticles (NPs) with a core/shell configuration. The ability of Escherichia coli cells supplied with H2 as electron donor to rapidly precipitate Pd(II) ions from solution is used to promote the reduction of soluble Au(III). Pre-coating cells with Pd(0) (bioPd) dramatically accelerated Au(III) reduction, with the Au(III) reduction rate being dependent upon the initial Pd loading by mass on the cells. Following Au(III) addition, the bioPd–Au(III) mixture rapidly turned purple, indicating the formation of colloidal gold. Mapping of bio-NPs by energy dispersive X-ray microanalysis suggested Au-dense core regions and peripheral Pd but only Au was detected by X-ray diffraction (XRD) analysis. However, surface analysis of cleaned NPs by cyclic voltammetry revealed large Pd surface sites, suggesting, since XRD shows no crystalline Pd component, that layers of Pd atoms surround Au NPs. Characterization of the bimetallic particles using X-ray absorption spectroscopy confirmed the existence of Au-rich core and Pd-rich shell type bimetallic biogenic NPs. These showed comparable catalytic activity to chemical counterparts with respect to the oxidation of benzyl alcohol, in air, and at a low temperature (90°C).

Paired box 6 (Pax6) is considered to be the master control gene for eye development in all seeing animals studied so far. In vertebrates, it is required not only for lens/retina formation but also for the development of the CNS, olfactory system, and pancreas. Although Pax6 plays important roles in cell differentiation, proliferation, and patterning during the development of these systems, the underlying mechanism remains poorly understood. In the fruit fly, Drosophila melanogaster, Pax6 also functions in a range of tissues, including the eye and brain. In this report, we describe the function of Pax6 in Drosophila eye-antennal disc development. Previous studies have suggested that the two fly Pax6 genes, eyeless (ey) and twin of eyeless (toy), initiate eye specification, whereas eyegone (eyg) and the Notch (N) pathway independently regulate cell proliferation. Here, we show that Pax6 controls eye progenitor cell survival and proliferation through the activation of teashirt (tsh) and eyg, thereby indicating that Pax6 initiates both eye specification and proliferation. Although simultaneous loss of ey and toy during early eye-antennal disc development disrupts the development of all head structures derived from the eye-antennal disc, overexpression of N or tsh in the absence of Pax6 rescues only antennal and head epidermis development. Furthermore, overexpression of tsh induces a homeotic transformation of the fly head into thoracic structures. Taking these data together, we demonstrate that Pax6 promotes development of the entire eye-antennal disc and that the retinal determination network works to repress alternative tissue fates, which ensures proper development of adult head structures.Pax6 | eyeless | twin of eyeless | eye-antennal disc | Drosophila

a b s t r a c tPalladium bioinorganic catalyst (bio-Pd) was manufactured using bacteria (Desulfovibrio desulfuricans and Escherichia coli) via the reduction of Pd(II) to bio-scaffolded Pd(0) nanoparticles (NPs). The formed Pd NPs were examined using electron microscopy and X-ray powder diffraction methods: a loading of 5 wt% Pd showed an average particle size of ∼4 nm. The catalytic activities of the prepared bio-Pd NPs on both bacteria were compared in two hydrogenation reactions with that of a conventionally supported Pd catalyst (Pd/Al 2 O 3 ). Concentration profiles of the different hydrogenation products were fitted using a Langmuir-Hinshelwood expression. In 2-pentyne hydrogenation, 5 wt% Pd E.coli achieved 100% of 2-pentyne conversion in 20 mins and produced 10.1 ± 0.7 × 10 −2 mol L −1 of desired cis-2-pentene; in contrast 5 wt% Pd/Al 2 O 3 yielded 6.5 ± 0.4 × 10 −2 mol L −1 of cis-2-pentene after 40 mins. In the solvent-free hydrogenation of soybean oil, the use of 5 wt% Pd E.coli yielded cis-C18:1 of 1.03 ± 0.04 mol L −1 and trans-C18:1 of 0.26 ± 0.03 mol L −1 (∼50% less of the latter than 5 wt% Pd/Al 2 O 3 ) after 5 h. Similar results were obtained using bio-Pd E.coli and bio-Pd D.desulfuricans . Bio-Pd was concluded to have the advantage of a lower cis-trans isomerisation in hydrogenation of alkyne/alkenes. Hence biomanufacturing is an environmentally attractive, scalable and facile alternative to conventional heterogeneous catalyst for application in industrial hydrogenation processes. D. desulfuricans is inconvenient to grow at scale but wastes of E. coli are produced from various industrial processes. 'Second life' (i.e. recycled from a pilot scale biohydrogen production process) E. coli cells were used to make bio-Pd catalysts. Although 'bio-Pd secondlife gave a slower conversion rate of 2-pentyne and soybean oil compared to bio-Pd from purpose-grown cells it showed a higher selectivity to the cis-isomer product.

How different cells and tissues commit to and determine their fates has been a central question in developmental biology since the seminal embryological experiments conducted by Wilhelm Roux and Hans Driesch in sea urchins and frogs. Here, we demonstrate that Polycomb group (PcG) proteins maintain eye specification by suppressing the activation of alternative fate choices. The loss of PcG in the developing eye results in a cellular reprogramming event in which the eye is redirected to a wing fate. This fate transformation occurs with either the individual loss of Polycomb proteins or the simultaneous reduction of the Pleiohomeotic repressive complex and Pax6. Interestingly, the requirement for retinal selector genes is limited to Pax6, as the removal of more downstream members does not lead to the eye-wing transformation. We also show that distinct PcG complexes are required during different developmental windows throughout eye formation. These findings build on earlier observations that the eye can be reprogrammed to initiate head epidermis, antennal and leg development.

No abstract